Robert Pietrusko, PharmD

Robert Pietrusko, PharmD serves as Chief Regulatory Officer and is a member of DBV’s Executive Committee responsible for Regulatory strategy and implementation on a global basis. He has directed the worldwide approval of more than 35 new products in multiple therapeutic areas. Recently, he led the Regulatory Affairs and Quality Assurance group at Vor Bio. As an early team member at Voyager Therapeutics, Dr. Pietrusko pioneered regulatory strategies to transition AAV gene therapies from research into the clinic. Prior to Voyager, he was Vice President of Global Regulatory Affairs & Quality and an Executive Officer at ViroPharma, Inc. He also served as Senior Vice President of Regulatory Affairs at Millennium Pharmaceuticals (now Takeda), spearheading the accelerated approval of Velcade® in the U.S. and in more than 90 countries worldwide. Earlier in his career, he was Vice President of Regulatory Affairs at SmithKline Beecham (now GSK) involving many therapeutic areas including antibiotics and vaccines.

He has played a key role in pioneering the concept of the Regenerative Medicine Advanced Therapy (RMAT) designation process. Dr. Pietrusko holds a Bachelor of Science and a Bachelor of Pharmacy degree from Rutgers University, and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Science. He completed his residency training in hospital pharmacy at Thomas Jefferson University Hospital and is the author or co-author of over 50 publications.